Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net margin is calculated as Net Income divided by its Revenue. Bausch Health's Net Income for the
three
months ended in Jun. 2026 was CHF206 Mil. Bausch Health's Revenue for the
three
months ended in Jun. 2026 was CHF2,280 Mil. Therefore, Bausch Health's net margin for the quarter that ended in Jun. 2026 was 9.05%.
The historical rank and industry rank for Bausch Health's Net Margin % or its related term are showing as below:
LTS:0QYW'
s Net Margin % Range Over the Past 10 Years
Min: -49.5 Med: -6.87 Max: 27.56
Current: -9.96
LTS:0QYW's Net Margin % is ranked worse than 75.23% of 961
companies
in the Drug Manufacturers industry
Industry Median: 5.34
vs LTS:0QYW: -9.96
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Bausch Health Net Margin % Related Terms
Bausch Health Net Margin % Historical Data
* Premium members only.
The historical data trend for Bausch Health's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch Health Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bausch Health's Net Margin % distribution charts can be found below:
* The bar in red indicates where Bausch Health's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch Health (LTS:0QYW) has a Net Margin % of 9.05% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Bausch Health and its competitors. According to the industry distribution chart, Bausch Health ranks #723 out of 961 companies in the Drug Manufacturers industry, placing it in the top 75.2%.
Is Bausch Health's Net Margin % too high?
Bausch Health's current Net Margin % is 9.05%. The Drug Manufacturers industry median Net Margin % is 5.34. Bausch Health's value of 9.05% is 69.5% above this industry median. Based on the distribution chart, Bausch Health ranks #723 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bausch Health has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bausch Health ranks #723 out of 961 companies for Net Margin %. This places Bausch Health in the lower half of its industry. The industry median Net Margin % is 5.34. Bausch Health's value of 9.05% is 69.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.34, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bausch Health's current Net Margin % of 9.05% is 69.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Bausch Health and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch Health's current Net Margin % is 9.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Bausch Health (LTS:0QYW) has a current Net Margin % of 9.05%. The stock's GF Value™ is CHF157.98, compared to a current price of CHF122.94 — trading 22.2% below its estimated fair value. The current Net Margin % is 9.05% and 69.5% above the Drug Manufacturers industry median of 5.34. Bausch Health's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Bausch Health (LTS:0QYW), the current Net Margin % is 9.05% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch Health (LTS:0QYW) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued.
The current stock price of CHF122.94 is trading 22.2% below its estimated GF Value™ of CHF157.98.
Key valuation signals for LTS:0QYW:
Net Margin %: 9.05%
GF Value™: CHF157.98 vs. price of CHF122.94 (22.2% below fair value)
Industry Position: 69.5% above the Drug Manufacturers median (#723 of 961)
No single metric tells the full story. See the LTS:0QYW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
65GF Score
Get the complete analysis for LTS:0QYW
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QYW has been successfully added to your 
